Kiniksa Pharmaceuticals, Ltd.
KNSA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 56.6% | 22.7% | 471.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 85.6% | 79.1% | 89.6% | 76.4% |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | -10.4% | -8.5% | 5.5% | -400.3% |
| Net Income | -$0 | $0 | $0 | -$0 |
| % Margin | -10.2% | 5.2% | 83.3% | -409.7% |
| EPS Diluted | -0.6 | 0.2 | 2.6 | -2.3 |
| % Growth | -400% | -92.3% | 213% | – |
| Operating Cash Flow | $0 | $0 | $0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | -$0 |